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1. INTRODUCTION 
Antineoplastic drugs are commonly used to treat cancers which are generally 
referred to as chemotherapy. The majority of antineoplastic drugs are non- selective in their 
action which exhibits their effects in both cancerous and non-cancerous cells in most 
organs and body tissues. Chemotherapy agents are known to be mutagens and carcinogens 
in animals, humans and in patients treated with therapeutic dose [1]. Cyclophosphamide 
(CP) is known to be human carcinogenic according to International agency for research on 
cancer (IARC Group I). 
Medical professionals were unaware of the risk from exposure to antineoplastic 
agents during performance of their daily routine. The routes of exposure are typically 
inhalation, dermal or oral. Workers may be exposed by inhalation via droplets, particulates 
and vapors when they create aerosols, generate dust by crushing tablets and clean up spills. 
Dermal exposure may occur when workers touch contaminated surfaces during preparation, 
administration or disposal of hazardous drugs and oral exposure may occur from hand to 
mouth contact. In most paper air sampling for antineoplastic drugs have little to no air 
borne contamination. Drugs particulates can become airborne after the drying of 
contaminated areas. Vaporization of antineoplastic agents has also been reported with 
various drugs such as carmustine, ifosfamide, thiotepa and CP [2, 3].  When food or 
beverages are prepared, stored or consumed in work areas, they may easily become 
contaminated with airborne particles of antineoplastic drugs. A potential source of exposure 
is direct skin contact when a spill or lack occurs and large volume of drug is released to the 
environment. Antineoplastic drugs can have chronic effects on reproduction, causing 
abortion, stillbirth, infertility and congenital abnormalities and other minor health effect 
include hair loss, headache, acute irritation and hypersensitive [4, 5]. 
Few methods have been described for the determination of CP in urine till now. The 
method used for the determination of CP is gas chromatography separation with nitrogen 
phosphorous detection or mass spectrometric detection. Other method used for analysis of 
CP is HPLC [6]. UV detection is not however, selective and sensitive enough to enable low 
exposure levels to be quantified because CP has weak chromophores [7, 8]. Polarographic 
and colorimetric methods have been described for the determination of CP and ifosfamide 
[9].    
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2. AIMS AND OBJECTIVE OF THE THESIS 
The main objective of this study was  
a) To optimize SPE method for isolation of organic compound such as CP from urine 
sample. Optimization is achieved by using different sorbent, matrix, washing 
solvent and elution solvent. Biological samples such as plasma and urine are much 
more complex due to presence of proteins, salts, acids, bases and various organic 
compounds with similar chemistry to analytes of interest. As a result, the extraction 
methods for biological samples have been complicated. If unsuitable sample 
preparation methods have been employed before injection, the entire analytical 
process can be wasted. The main task is to remove maximum interfering substance 
from urine matrix and conversion of analytes into a more suitable form for injection.  
b) To optimize the separation conditions of the HPLC-MS/MS analysis to achieve the 
optimal (short retention time, no interferences) cyclophosphamide separation. 
Optimization is achieved by changing different parameter such as 
  
Mobile phase and its composition 
Flow rate 
Scan type  
c) After developing suitable analytical method, this SPE-LC-MS/MS method is 
applied for the analysis of urine samples of health workers from Medical University 
of Gdansk, who were exposed with CP during their work in pharmacy. Hospital 
workers are exposed to antineoplastic drugs via dermal, inhalation route during 
preparing and handling.         
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3. THEORITICAL PART 
CP general information 
3.1. Cyclophosphamide 
CP (2-[bis(2-chloroethyl)amino] tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) is 
an alkylating agent that is frequently used as an antineoplastic drug. CP is a prodrug that 
requires activation by the cytochrome P450 enzyme system to form its pharmacologically 
active metabolite 4- hydroxycyclophosphamide [10]. The metabolites are genotoxic due to 
their ability to cross-link DNA and thereby cause DNA damages. CP is classified as 
carcinogenic to humans [11]. It has very narrow therapeutic index [12]. CP is rapidly 
converted to number of mutagenic and carcinogenic products, some of which have been 
isolated from urine [13].  
3.1.1. Physical and chemical properties of CP 
Basic physical and chemical properties of CP [11, 14-17] are summarized below in Table 1.                    
Table 1 Physical and chemical properties of CP  
 
Chemical structure 
 
Molecular formula  C7H15Cl2N2O2P     
Molecular weight 261.09 
Physical properties Odorless, fine white crystalline powder 
Melting point 49.5 – 53 ° C 
Boiling Point  336° C 
Density 1.479 g/cm3
Solubility Soluble in chloroform, dioxane and glycols; slightly soluble in  
benzene, carbon tetrachloride, very slightly soluble in ether and  
acetone. 
Partition coefficient 0.63 
pKa 4.5-6.5 
Stability Hydrolysis occurs at temperatures above 30 °C, with removal of  
chlorine atoms. Sensitive to oxidation, moisture and light.     
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3.1.2. Metabolism of CP 
CP is a prodrug which metabolized to both active and inactive metabolilites, as 
shown in figure 1. CP is activated by hepatic microsomal mixed function oxidases 
cytochrome P450 to form 4–hydroxycyclophosphamide (4-OHCP), which exists in 
equilibrium with its tautomer aldophosphamide (AldoCP). 4-OHCP is very unstable, 
readily diffuses in to cells and spontaneously decomposes into phosphoramide mustard 
(PM) by ß elimination of acrolein [18]. PM is an active alkylating species which is 
responsible for alkylating effect of CP [19]. Acrolein is an unwanted by product which may 
enhance CP-induce cell damage, possibly by depletion of cellular glutathione by 
conjugation [20]. The aldehyde dehydrogenase enzymes are involved in formation of 
carboxyphosphamide (CarboxyCP) from aldophosphamide [21]. 4- Ketocyclophosphamide 
(4-KetoCP) are formed due to oxidation of 4-OHCP by alcohol dehydrogenase. Other 
inactive metabolite includes 2-dechloroethylcyclophosphamide (DCCP) produced by 
separate oxidative N-dealkylation reaction [22].  
 
Figure 1. Metabolism of cyclophosphamide. 
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3.1.3. Absorption, distribution and elimination of CP 
CP is well absorbed orally, with peak concentrations occurring after 1-3 hours and 
has bioavailability of 85-100% [23]. The drug is rapidly absorbed from the blood after IV 
injection [11]. 
CP is distributed with a volume of distribution of 30 -50 L, which approximates to 
the total body water [10]. Penetration of CP and its metabolites into body fluids is limited. 
Metabolites like CarboxyCP and DCCP were not found in cerebrospinal fluid whereas PM 
and CP could be detected [24, 25].  
CP and its metabolites are eliminated by urine in 24 hours after the start of 
treatment. The major function of CP in the body is eliminated by hepatic metabolism, but 
small fraction is eliminated by renal excretion of unchanged drug in urine. Less than 20 % 
of the administered dose is eliminated unchanged in the urine. Between 30-60% of the total 
CP dose is eliminated renally as CP or metabolites. CarboxyCP is major metabolites found 
appearing in urine [26, 27]. Small fraction of CP dose is eliminated via feces and expired 
air. In children and young adults plasma half life is shorter than adults. The elimination half 
life of CP ranges between 5-9 hours over a large concentration range. Total systemic 
clearance of CP ranges from 4-5 L/h of which the greater part is non-renal clearance. The 
plasma half life of CP is approximately 5 h in human during the first day after the dose 
[29].  
3.1.4. Mechanism of action of CP 
First CP is converted by the liver into two chemicals acrolein and phosphoramide. 
Acrolein and phosphoramides are the active compounds that prevent cell division by cross-
linking DNA strands and decreasing DNA synthesis. These drugs can’t distinguish between 
normal and cancerous cells. CP also possesses potent immunosuppressive activity [30].       
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3.1.5. Cyclophosphamide use: 
CP has been widely in different disease treatments: 
 
Breast cancer [31-33] 
Ovarian cancer [34] 
Prostate cancer [35-38] 
Lung cancer [39,40] 
Lupus erythematosus [41,42] 
Rheumatoid arthritis [43,44] 
Multiple Sclerosis [45,46] 
Idiopathic pulmonary fibrosis [47-48] 
Wegener granulomatosis [49-51] 
Hodgkin’s Lymphoma [52-54] 
Thrombocytopenic purpura [55-58] 
Polyarteritis nodosa [59] 
Anemia [60,61]                 
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Analytic of CP 
3.2. Solid Phase Extraction (SPE): 
SPE is one of the techniques available to an analyst to bridge the gap that exists 
between the sample collection and analysis step. In SPE, extraction is performed by 
absorbing the analyte from the matrix onto a solid sorbent. The solid phase is then 
separated from the solution and other solvents added. The first solvent is usually a wash to 
remove possible adsorbed matrix components; eventually an eluting solvent is brought into 
contact with sorbent to selectively desorb the analyte. 
Today SPE is the most popular sample preparation method. SPE is choice of 
method when handling biological samples for liquid chromatography (LC), a sample is 
mandatory to limit column clogging, presence of co-eluting substances as well as matrix 
effects frequently encounter with mass spectrometric detection. SPE allow good sample 
clean up. 
It is a very active area in the field of separation science [62-65]. Liquid-liquid 
extraction (LLE) has remained the preferred technique for the preparation of the liquid 
samples for several years especially in the environmental field. LLE is labor intensive, 
difficult to automate, and is frequently plagued by practical problems, such as emulsion 
formation. In addition, it consumes relatively large volumes of high-purity solvents with 
expensive disposal requirements [66]. The increased development of SPE has occurred 
during the past five or six years; with many improvements in formats, automation and 
introduction of new phases. One reason was the pressure to decrease organic solvent usage 
in laboratories which has encouraged the requirement for solvent free procedures and has 
greatly contributed to the growth of SPE at the expense of LLE procedure [67]. Other 
reasons for the growing interest in SPE techniques are the large choice of sorbents with the 
capability for new ones of trapping analytes, shorter processing time and simpler procedure 
[68]. 
The general procedure of SPE is to load a solution onto the SPE phase, wash away 
undesired components and then wash off the desired analytes with another solvent into a 
collection tube.    
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3.3. Literature review 
Literature review concerning CP extraction and analyses has been summarized in table 2. 
Table 2 Literature review presenting different methods of extraction and analysis of CP.   
Drugs Matrix Sample 
Preparation 
HPLC Parameter Mobile phase MS Reference   
CP            
Urine 
Liquid-Liquid Hypersil BDS C8 
150 
 
4.6 mm,   5 µm 
Solvent A: 
Methanol 
Solvent B: 
0.02 M ammonium acetate, pH 4.5 
Triple 
quadrupole 
mass 
spectrometer 
[69] 
CP and metabolites 
(DCL-CP, 4KetoCP, 
CarboxyCP ) 
- Beta Basic C8 
100 3 mm, 5 µm 
Solvent A: 
Water with 0.1% formic acid 
Solvent B: 
Methanol 
MS/MS [70] 
CP and other drugs 
(IF, Doxorubicin, 
Epirubicin 
Daunorubicin) 
SPE Hypersil BDS C8 
150 4.6 mm,   5 µm 
Solvent A: 
Water + 0.1 % formic acid 
Solvent B: 
Acetonitrile +0.1 % formic acid 
Triple 
quadrupole 
mass 
spectrometer 
[12] 
Metotrexate 
CP  
SPE Max RP Capillary 
column 
0.5 50 mm, 4 µm 
Solvent A: 
20 mM ammonium acetate, pH 4 
with acetic acid 
Solvent B: 
Methanol 
Triple 
quadrupole 
mass 
spectrometer 
[71] 
CP LLE GC- 
Methyl siloxen 
capillary column 
30 m  0.25 mm, 
film thickness0.25µm 
- GC-MS [72] 
CP Urine  
Plasma 
Centrifuged the 
sample for 5 
min. 
Genesis C18 
50 2.1mm, 4 µm 
Solvent A: 
0.5 % acetic acid 
Solvent B: 
Methanol with 0.5 % acetic acid 
Triple 
quadrupole 
mass 
spectrometer 
[73] 
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CP and  other drugs 
(Doxorubicin, 
Doxorubicinol)         
Plasma   
SPE 
Symmetry C18 
30 
 
2.1 mm 
Solvent A: 
5 mM acetate buffer, pH 3.5 
Solvent B: 
Methanol 
Triple 
quadrupole 
mass 
spectrometer 
[74] 
CP and metabolites 
(4-OHCP) 
Centrifused  for 
15 min. 
Zorbax Extend C18 
analytical column 
150 2.1 mm, 5 µm 
Solvent A: 
1 mM ammonium hydroxide in 
water , pH 10 
Solvent B: 
Acetronitrile 
Triple 
quadrupole 
mass 
spectrometer 
[75]    
CP and metabolites 
(4- OHCP, 
CEPM)             
Plasma  
Centrifused for 
5 min. 
Zorbax Extend 
50 2.1 mm, 5µm 
Solvent A: 
Water: methanol 
Solvent B: 
1o mM ammonium acetate pH 8.5 
Single 
quadrupole 
[86]  
CP and metabolites 
(4KetoCP 
CarboxyCP 
3- 
Dechloroethylifosfamide)  
SPE Ultrasep ES 100 
Pharm 
RP18 ( 125 2 mm, 
5µm 
Solvent A: 
Methanol 
Solvent B: 
20 mM ammonium acetate with 1 
% acetic acid. 
Single 
quadrupole 
[77] 
CP and metabolites 
(4KetoCP 
CEPM 
4-OHCP 
DCCP) 
Centrifused Zorbax SB-C8 
15cm 4.6 mm 
Solvent A: 
Methanol 
Solvent B: 
10 mM ammonium acetate ,pH 4  
Micromass 
Quattro II 
tandem 
quadrupole 
mass 
spectrometer 
[78] 
CP and other drug 
IF 
SPE 
LLE 
Supelcosil LC-18 
150 4.6 mm, 
5µm  
Solvent A 
10 mM phosphate buffer pH6 
Solvent B 
Acetonitrile 
(75:25) 
- [79] 
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CP and other drug 
IF     
Urine   
Wipe 
samples  
Liquid- Liquid 
extraction 
Hypersil C8 BDS 
15 cm 
 
4.6 mm, 5 
µm 
Solvent A: 
Methanol 
Solvent B: 
0.02 M acetate buffer pH 4.0 
Triple 
quadrupole 
mass 
spectrometer 
[83] 
CP - GC - GC-MS/MS [81]  
CP - GC - GC-MS/MS [82]  
CP and other drugs 
Methotrexate 
5-Fluorouracil      
Wipe 
sample 
-  
Synergi 4u Max RP 
capillary column 
0.5 50 mm, 5µm  
Solvent A: 
20 mM ammonium acetate pH 4 
Solvent B: 
Methanol  
Triple 
quadrupole 
mass 
spectrometer   
[76] 
CP and other drugs 
Taxol 
Gemcitabine 
SPE  Solvent A: 
0.1 % HCOOH in distilled water/ 
acetronitrile (80:20v/v) 
Solvent B: 
0.1 % HCOOH in distilled 
water/ACN (30:70 v/v) 
Triple 
quadrupole 
mass 
spectrometer 
[80] 
CP and metabolite 
(OH-CP) 
Mouse 
plasma and 
tissue 
Centrifused for 
5 min. 
YMC C18 basic 
column 
50 2 mm, 5µm 
Solvent A: 
ACN 
Solvent B: 
0.1 % formic acid 
LC-MS/MS [85] 
CP 
Water Lyophilization 
extraction 
Nucleosil   C18 
0.2 10 cm, 3 µm 
Solvent A: 
Ammonium formate buffer pH 5.7 
Solvent B 
Methanol 
MS/MS [14] 
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4. EXPERIMENTAL PART 
4.1. Chemicals and reagents 
 
Ammonia ( POCH, Poland ) 
Cyclophosphamide (Baxter, Poland ) 
Deionized water ( 0.22 µm, Hydro lab HLP 5, Poland) 
Dichloromethane ( POCH, Poland ) 
Ethyl acetate ( POCH, Poland ) 
Formic acid 80 % ( POCH, Poland ) 
Hydrochloric acid ( POCH, Poland ) 
Methanol  ( J.T. Baker, Holland ) HPLC grade, LC-MS grade, HPLC gradient grade 
Nitrogen gas ( Oxygen S.C., Poland ) 
Potassium dihydrogen phosphate (KH2PO4 ) ( POCH, Poland ) 
Potassium hydrogen phosphate (K2HPO4  ) ( POCH, Poland ) 
Sodium hydroxide ( POCH, Poland )  
4.2. Apparatus and Laboratory equipment 
Disposable pipette tips ( Eppendorf, Germany ) 
Laboratory glassware (volumetric flask, measuring cylinder, beaker) 
Microliter Syringe 10 µL, 50 µL ( Hamilton, USA ) 
Magnetic stirrer 
pH meter Basic 20+ ( Crison, Spain) 
Pipettes model (P10, P100, P2500) ( Eppendorf, Germany ) 
4000 Q Trap mass spectrometer (Applied Biosystems MDS SCIEX ) 
Refrigerator (Siemens, USA) 
Sonicator ( Labart Sp. z o.o, Poland ) 
Series 1200  HPLC ( Agilent Technologies, Palo Alto, CA, USA)  
Syringe filter device 
Turbo Vap LV Evaporator  ( Caliper Life Science, USA) 
Ultra low temperature freezer (New Brunswick, USA) 
Visiprep SPE vacuum manifold ( Sigma- aldrich, USA ) 
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Weighing balance ( Mettler Toledo, USA) 
SPE Cartridges from different manufacturers are summarized in Table 3.  
Table 3 Cartridges applied for SPE during CP isolation from urine sample 
Sorbent Manufacturer Mass/ 
Volume 
(mg/mL) 
Porosity 
(Å) 
Particle 
diameter 
(µm) 
End-
capping 
% 
Carbon 
Chromabond easy           Machery–Nagel           200/6                  50                80                  n.a                 n.a 
Chromabond C18 ec        Machery–Nagel            1000/6               60                45                  Yes               14 %  
Lichrolut RP-select B      Merck                           200/3                 n.a              40-63              n.a                 n.a 
Octadecyl                         J.T. Baker                     500/3                47-60           n.a                 Yes               17-18 
Oasis HLB                       Waters                           150/6                80                 30                  n.a                 n.a 
Strata- X                          Phenomene                    200/3                85                 33                  n.a                 n.a 
Zorbax C18                     Agilent                           200/3                80                 50                   No                11   
4.3. Analytical procedure 
4.3.1. Chromatographic conditions 
HPLC analysis was performed by injection volume 50 µL of the sample onto the 
Lichrospher® 100 RP-18 column (125 4 mm) with particle size of 5 µm (Merck, 
Germany). The column outlet was coupled with to an ESI 4000 Q Trap mass spectrometer 
(Applied Biosystems MDS SCIEX) equipped with an electrospray ionization. 
The flow rate was 1000 µL/min. The mobile phase, under gradient conditions, was 
as follows: mobile phase A, methanol; mobile phase B, 10 mM ammonia and formic acid 
buffer adjusted to pH 3; time program, 0, min 20 % A/80 % B; 7 min, 80% A/20% B; 9 
min, 80% A/20% B; 10 min, 20% A80% B and this mobile phase composition was 
maintained for 4 minutes. Total run time was 15 min.  
4.3.2. Mass spectrometry parameters 
MS/MS analysis was performed on the 4000 Q Trap triple quadrupole mass 
spectrometer equipped with an electrospray ionization (ESI) source operating in positive 
ion mode. Analyst software (Applied Biosystems/ MDS Sciex, Analyst software version 
1.5) was used for the instrument control and data collection. The instrument was operated 
in multiple reaction monitoring (MRM) mode and the following ion transition       
(Precursor      product) were monitored: m/z 261.00        140.00. The elctrospray voltage 
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was 5000 V and dwell time was 200 msec. Curtain gas (CUR) 40 psi; collision energy (CE) 
31 V; declustering potential (DP) 80 V; collision cell exist potentials (CEX) 22 V were 
used for the analysis of CP.  
4.3.3. Preparation of stock and working standard solutions 
Stock solution was prepared by dissolving 25.0 mg of pure CP drug in 25.0 mL of 
methanol to give concentration of 1.0 g/L. Stock solution was stored at refrigerator (4°C). 
Working standard solution was prepared weekly by diluting 10 µL of stock solution in 10 
ml of volumetric flask using mixture MeOH: Water (1:1) as a solvent, it was kept at 4°C. 
Final concentration of CP was 1 µg/mL.  
4.3.4. Urine collection: 
Urine samples from fifteen health workers from Medical university of Gdansk who 
handle CP were collected in 100 mL of bottles. Two blank samples were collected from six 
year old boy and 26 year old girl. Table 4 shows the characteristics of health workers. 
Collected urine samples were labeled and stores at – 80°C until sample preparation. Sample 
preparation was done after bringing the urine sample in ambient temperature. No drug 
spillage or accidents were reported in connection with the urine sampling.   
Table 4: Characteristics of health workers          
Person              Sex           Person            Sex 
1                        F                  8                    F 
2                        F                  9                    F 
3                        F                 10                   F 
4                        F                 11                   F 
5                        F                 12                   F 
6                        F                 13                   F 
7                        F                  14                  F  
                                             15                   M   
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4.3.5 Comparison of LC-MS and LC-MS/MS in term of sensitivity 
The limit of detection (LOD) and limit of quantification (LOQ) were determined by 
analyzing blank urine spiked with working standard solution. LOQ was determined by 
comparing the measured signals of the samples with known low concentrations of analytes 
to those of blank samples, thereby establishing the minimum amount of compounds that 
could be reliably quantified with signal to noise ratio 10:1. LOD and LOQ were, 
respectively, defined as three and ten times the standard deviation of the LC-MS/MS and 
LC-MS peak areas detected at the retention times of the analytes of interest.  
Table 5 Sensitivity comparison of LC-MS and LC-MS/MS 
Linearity         LC-MS        LC-MS/MS 
LOD      9.36 µg/mL        0.27 ng/mL  
LOQ       93.6 µg/mL        0.54 ng/mL    
    
For CP detection limits, 1000 times lower sensitivity with LC-MS operating in the SIM 
mode than with the triple quadrupole were achieved. In terms of sensitivity and selectivity 
LC-MS/MS is markedly superior.   
4.3.6. SPE extraction 
The most important parameters in SPE are the selection of the type and amount of 
the sorbent, the determination of the sample volume that can be applied without loss in 
recovery, the composition and volume of the washing solution that can be applied without 
loss of the analytes, and finally the composition and volume of the elution. 
For optimizing SPE methods different parameters were changed such as the 
cartridge stationary adsorbent, pH, solvent used for cleaning, solvent used for elution and 
elution volume. SPE methods were carried out using different cartridge such as Octadecyl 
from J.T. Baker (500 mg/3mL), Chromabond C18 ec from Machery- Nagel (1000 mg/6mL), 
Strata- X from phenomene  (200 mg/3mL), Lichrolut RP- select B from Merck (200 
mg/3mL), Oasis HLB from Waters  (150 mg/3mL), Zorbax C18 from Agilent (200 mg/mL), 
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Chromabond Easy from Machery- Nagel (200 mg/mL). Among them recovery values were 
higher with Oasis HLB and Strata- X. So further analysis were carried out using Strata-X.   
Buffer PBS pH 7, buffer pH 3, urine adjusted to pH 3, normal urine were used to 
see the recoveries. Normal urine has high recovery so analysis was carried out with it. 
For cleaning different solvents were used such as water, buffer PBS pH 7, buffer pH 
3 and methanol: water (1:1). In order to remove interference from the analyte mixture of 
methanol: water (1:1) was used.  
Whereas for elution dichloromethane, methanol were checked. To see the impact 
different elution volume (1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, and 8ml) were used and it 
was found that 3ml was enough to elute the analyte.                       
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SPE procedure used for CP determination in urine samples has been shown on figure 2.                              
Figure 2 Schematically presentation of SPE procedure 
Cleaning 
 
2 mL of H2O 
1 mL of MeOH:H2O 
(1:1)
SPE column drying  
Nitrogen(N2) stream  
Elution of analytes 
3 1 mL of CH2Cl2  
Evaporation of solvent 
Using Turbo evaporator 
with N2   stream 
Re-dissolution 
Redissolved with 1 ml 
of MeOH: H2O (1:1) 
HPLC-MS/MS Analysis   
Sample volume 
5 mL  
Conditioning of the cartridge 
2 3 mL of MeOH 
 
2 2 mL of H2O 
Load 
5 mL of urine  +  
     5 µL of  0.936 µg/mL CP 
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4.3.7. Calibration 
Calibration curves were prepared with known concentrations of CP: 
1) diluted in methanol: water (1:1) 
2) spiked in 5ml of blank urine 
Five calibrations standards were made by adding working solution of CP to 1 mL 
methanol: water (1:1) and directly analyzed. The CP concentrations of the standard were 
0.608, 1.17, 2.34, 4.68, 9.36 ng/mL. 
 
Figure 3 Calibration curve of CP diluted in methanol: water (1:1).  
Calibrations urine samples were prepared by spiking human urine samples from 
unexposed subject (blank urine) with CP, in order to obtain five concentration (0.187, 
0.374, 0.936, 1.4, 1.87 ng/mL). Calibration samples were extracted following the above 
described procedure and analyzed by HPLC-MS/MS.  
Figure 4 Calibration curve of urine sample spike with CP. 
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5. RESULTS AND DISCUSSION 
5.1. Mass spectrometry 
In ESI positive ion mode the compounds yielded abundant [M+H]+ ions. This protonated 
molecule at m/z 261 for CP was selected as the precursors ions for the MS/MS 
fragmentation of the analyte. The most abundant fragment was detected at m/z 140 and 
proposed fragmentation is shown in figure 6. 
Cleavage of the nitrogen-phosphorus bond gave fragment ion at m/z 140, resulting in the 
loss of di(2-chloroethyl) amine. The transition from m/z 261 to 140 was used in MRM 
analysis. The MRM parameter and precursor- product ion combinations used are 
summarized in table 6.  
Table 6 MRM parameters  
Compound                    Retention time                    Precursor ion                    Product ion 
  CP                                      6.75  min                             261.0                                  140 
 
Figure 5 HPLC-MS/MS working in MRM mode obtained for CP standard solution. 
Proportion of CP fragmentation has been included. 
26  
Figure 6 (a) shows result for blank urine sample and (b) shows a typical MRM 
chromatogram corresponding to a blank urine sample spiked with 4.68 ng/mL of CP. No 
interfering peaks were presented at the retention time of CP.  
 
a) 
      
b) 
Figure 6 The HPLC/MRM chromatograms a) for a blank urine sample and b) for a blank 
urine sample spiked with 0.936 µg/mL of CP.  
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5.2. Liquid Chromatography: 
The elution gradient and influence of mobile phase pH were studied in order to optimize 
the analytical performance. A short analytical column and elution gradient with 10 mM 
formic acid with ammonia buffer pH 3 and methanol were chose as the best compromise 
between retention time and ionization of analyte. Under these chromatographic conditions, 
CP was separated in 15 min in a flow rate 1 mL/min.   
5.3. Linearity 
Calibration curves showed high linearity over the concentration range                
0.187 -1.87 ng/mL with correlation coefficient greater than 0.998.  
5.4. Sensitivity 
The limits of detection (LOD) and LOQ were determined by analyzing blank urine 
samples spiked with the working standard CP. LOD and LOQ were found to be 0.27 ng/mL 
and 0.54 ng/mL. These values allowed the analysis of CP in human urine sample at trace 
level.  
5.5 Carry over 
To determine the carry over, blank samples were injected after a sample. No carry 
over from analytes were seen in blank sample.  
5.6 Recovery 
The recovery was determined using urine sample spiked with CP (5 µL of 0.936 
µg/mL in 5 mL urine). Final concentration in urine was 4.68 µg/mL.  The obtained peak 
areas of the spiked urine standards at these levels after sample preparation were compared 
with the peak areas resulting from aqueous standard solutions at the same concentrations 
without sample preparation.      
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5.7. Influence of solvent used to prepare CP standard solution: 
CP at concentration 4.68 ng/ml was prepared in five different solvent: 
a) Methanol 
b) Methanol: Water (1:1) mixture 
c) Urine: Water ( pH=3) mixture (1:1) 
d) Urine: Buffer (pH=3) mixture (1:1) 
e) Buffer pH=3  
Data obtained from CP diluted in MeOH: Water (1:1) mixture have been treated as 100 %, 
therefore CP diluted in all the other solutions gives different recoveries, as shown in     
figure 7.   
 
Figure 7 Influence of solvent used to prepare CP standard solution.  
Analysis of these CP solutions gave different chromatograms, as it has been presented in 
figure 8. It was found that methanol: water (1:1) mixture give highest peak area whereas 
those dilutions of CP with urine sample show very low recovery. Also baseline and peak 
shape of CP are not good probably due to presence of interferences.   
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  Figure 8 CP diluted in a) methanol b) methanol: water (1:1) c) mixture urine: water (1:1)    
pH=3 d) urine: buffer pH=3 mixture e) buffer pH=3.   
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5.8. Matrix effects 
Urine is a complex biological material, which contains urea, creatinine, uric acid, 
hormones, pigments and mucins. Some of them can influence extraction process using SPE 
(deactivation of active points at the surface of sorbent, sorption, blocking of flow channels). 
Therefore, the way the urine sample is treated before sorption in SPE can be crucial for 
recovery of CP. Urine samples, after spiking with CP were prepared in four different ways: 
a) 5 mL urine + 2 mL PBS buffer (pH=7) 
b) 5 mL urine + 2 mL buffer (pH=3) 
c) 5 mL urine acidified with ammonia to pH=3. 
d) Urine 
CP was isolated from samples using SPE and recovery of CP has been shown in figure 9.  
 
Figure 9 Influence of sample preparation of urine before SPE on recovery of CP. 
No significant difference has been observed between urine samples prepared before 
SPE in different way, especially in case of Oasis HLB, Lichrolut RP-select B, Chromabond 
C18 ec and Chromabond Easy sorbent. For SPE, urine sample without pretreatment were 
used for carrying the experiment.    
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5.9. Influence of time of evaporation on recovery 
A set of six different CP solutions in MeOH has been prepared. The content of CP 
was constant (4.68 ng/mL) but amount of MeOH was different (1 mL, 2 mL, 3mL). Solvent 
was removed using Turbo evaporator. Temperature was set on 40° C and gas pressure was 
4 psi. Differences in solvent amount should result in differences in evaporation time. Dry 
residue was re-dissolved in the mobile phase (mixture MeOH: water 1:1, v/v) and analyzed. 
Results, in the form of recovery calculated according to CP standard solution without 
evaporation treated as 100 % are shown in Table 7.  
Table 7 Influence of time of evaporation on recovery 
 
Time required for sample  
evaporation 
   Recovery  % 
(R1) 
Recovery  % 
(R2) 
Approx. 20 min. (MeOH 1 mL) 91 93  
Approx. 40 min. (MeOH 2 mL) 89 93 
Approx. 60 min ( MeOH 3 mL) 94 137 
Sample having only 1 ml of methanol evaporates faster than sample containing 2 ml and 3 ml of 
solvent. Each 1 mL of MeOH needs approximately 20 minutes for complete evaporation. From 
table 7 we can conclude that there is no influence of time of evaporation on CP recovery. 
Recovery ranged from 89 to 94 % except in one sample where recovery is 137 %, this is due to 
human error.         
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5.10. Sorbent types 
     To check best sorbent seven different type of cartridge such as  J.T baker ( Octadecyl ), 
Chromabond C18  ( Octadecyl), Strata-X from Phenomena ( Polymeric surface modified styrene- 
divinylobenzene), Merck Lichrolut RP-select, Agilent Zorbax C18 (monomeric bonding, carbon 
loading 11 %), Waters Oasis HLB cartridge (hydrophilic-lipophilic balance sorbent reversed 
phase sorbent polymeric water- wettable reversed phase sorbent), Chromabond Easy ( polar 
modified polystyrene- divinylbenzene copolymer with weak anion exchanger) were used.  
 
Figure 10 Influence of sorbent on CP recovery  
Oasis, Strata, Merck and Zorbax give high recovery. So, analyses were carried out using    
Strata-X.       
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5.11.Influence of different eluent solvent on recovery: 
Methanol, dichloromethane, methanol: water (1:1), methanol and ethyl acetate solvents were 
used for eluting the analyte in order to find suitable elution solvent. Elution was performed by 
adding 3 mL aliquots of different eluting solvent as mention above except methanol: water (1:1) 
mixture, passing them through under vacuum and collecting them separately, dried and 
analyzed. Whereas in case of methanol: water (1:1) elution was performed by using 1 ml and 
analyzed directly.   
 
Figure 11 Influence of different eluent solvent on CP recovery.   
Using methanol: water (1:1) solvent, analyte was not eluted. Whereas methanol, 
dichloromethane, methanol and ethyl acetate were good solvent for eluting the CP from 
cartridge. Among three, dichloromethane show high recovery of CP in Stata –X catridge.  Thus, 
dichloromethane was found suitable eluting solvent for CP analyte.       
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5.12. Stability study of CP solutions 
In order to observe the degradation process of CP in respect to time extract from urine 
samples were kept at ambient temperature and after the degradation process started they were 
moved to refrigerator at 4 °C. All extracts and CP standard solution were dissolved in the 
mixture MeOH: H2O (1:1) and were kept in transparent vials. All the samples were analyzed 
after every three days and recoveries were calculated (Table 8) according to results obtained the 
very first day of analysis (100 %).  
Table 8 Degradation of CP in time 
Sorbent used  
Recovery [ %] 
Day 1 Day 3 Day 6 Day 9 
  
Extract from urine sample with buffer pH=3 
Extract from Chromabond C18 ec  100 71 46   
Extract from Chromabond easy  100 73 60 53 
Extract from Octadecyl  100 50 37 33 
Extract from oasis HLB 100 51 37 29 
Extract from Lichrolut RP- select  100 48 37 33 
Extract from Strata- X  100 48 36 32 
Extract from Zorbax C18  100 38 29 26   
Extract from urine sample with PBS  buffer pH=7 
Extract from Chromabond C18 ec  100 92 77 69 
Extract from Chromabond easy  100 78 70 59 
Extract from oasis HLB  100 54 43 38 
Extract from Lichrolut RP- select B 100 -   - -  
Extract from Strata- X  100 50 39 35 
Extract from Zorbax C18  100 59 48 43 
Recovery of CP was found almost half reduced after keeping the extract at ambient temperature 
which represented in Figure 13 and 14. These results indicated an approximately deterioration 
of 50 percent in day 3 and approximately 67 percent over day 9. This information supports that 
both standard and samples should be analyzed as soon as possible after the samples are 
collected to avoid error due to loss of potency. Depending on the environmental conditions in 
which organic compounds are present, they can undergo changes resulting from chemical, 
biological or photochemical reactions. Photo degradation and biodegradation are major 
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degradation processes which can naturally happen. Photo degradation, as a chemical reaction 
that occurs under the influence of photons or light, could take place and cause decrease of CP 
content in the extract. We believe that bacteria presented in urine samples were removed during 
SPE. However, we do not have scientific proof because it was not the subject of the 
investigations.  
 
Figure 12 Stability study of extract urine (urine samples diluted with buffer pH=3).  
Figure 13 Stability study of extract urine (urine samples diluted with PBS buffer pH=7)  
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6.  APPLICATION OF THE METHOD 
To assess the feasibility and effectiveness of this SPE- LC-MS/MS method, urine 
samples of health workers were collected and analyzed. Fifteen samples were collected and 
store at – 80 °C until analysis. Two blank samples were collected from six year boy and 
twenty six year old girl.  Spiked sample was prepared and analyze. Chromatogram is shown 
below (Figure 14). The CP results were below the analytical detection limits in all samples. 
  
   Figure 14 Chromatogram of a) spiked sample b) standard c) health worker.   
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7. CONCLUSION  
According to IARC, CP is human genotoxic carcinogen [1, 11]. Several reports 
have discussed exposure to CP during occupational activities and concluded that it should 
be avoided because any detectable level is considered to be hazardous. In order to obtain 
accurate measurements of CP in urine samples SPE methods was optimized. Optimization 
of SPE method was carried out by changing different parameter such as different type and 
amount of sorbent, composition and volume of elution, washing solvent. SPE was effective 
with no interfering peaks from matrix compound and recovery was above 75%. 
After optimizing SPE method, CP separation conditions of the HPLC-MS/MS 
analysis was achieve by changing different parameter such as suitable mobile phase and its 
composition, flow rate, scan type, polarity. LC/MS/MS detection was performed using 
triple quadrupole mass spectrometer working in MRM mode. The samples were prepared 
using SPE and analyzed using a gradient separation. Total analysis time was 15 minute. 
Calibration curve were made to see the instrument performance and SPE procedures which 
show good linearity. 
A sensitive, specific and accurate HPLC/MS/MS has been developed for the 
analysis of CP in human urine. This SPE-LC-MS/MS method was applied for the analysis 
of urine samples of health workers. Fifteen samples urine was collected from Medical 
University of Gdansk, who were exposed with CP during their work in pharmacy. Two 
blank samples were collected from six year boy and twenty six year girl. In all sample CP 
was found below LOD.   
The stability of the CP was studied. Analyses were conducted on the day prepared 
(day 1) and days 3, 6 and 9. These results indicated an approximately deterioration of 50 
percent in day 3 and approximately 67 percent over day 9. This information supports that 
both standard and samples should be analyzed as soon as possible after the samples are 
collected to avoid error due to loss of potency.     
38  
8. SUMMARY 
Biological samples urine are much more complex due to presence of proteins, salts, 
acids, bases and various organic compounds with similar chemistry to analytes of interest. 
As a result, the extraction methods for biological samples have been difficult. The main 
task was to remove maximum interfering substance from urine matrix and conversion of 
analytes into a more suitable form for injection. Therefore, optimization of SPE method 
was done by changing different parameter such as different type and amount of sorbent, 
composition and volume of elution, washing solvent. The use of 24 well SPE plate for 
matrix purification significantly allows the use of small urine and solvent volumes, reduces 
the sample preparation time and ensures a high throughput, thus allowing the routine 
biological monitoring of CP as indices of human exposures. In order to investigate the 
effectiveness of the SPE method tests were repeated on Strata-X cartridge and method 
showed good recovery (above 75 %) of CP. 
After optimizing SPE method, CP separation conditions of the HPLC-MS/MS 
analysis was achieve by changing different parameter such as suitable mobile phase and its 
composition, flow rate, scan type, polarity. The LC separation was performed on 
Lichrocart® 100 RP-18 column (125  
 
4 mm, particle size of 5 µm) with 1 mM formic 
acid with ammonia buffer pH 3 and methanol using gradient program at a flow rate 1 
mL/min with total run time 15 min. A reversed phase HPLC system was interfaced with an 
ESI source coupled to tandem mass spectrometry. The triple quadrupole mass spectrometer 
was operated in positive ion mode and MRM was used for analysis of CP. LOD and LOQ 
were 0.27 ng/mL and 0.54 ng/mL. A sensitive, specific and accurate HPLC/MS/MS has 
been developed for monitoring CP in urine samples. The use of reversed phase HPLC 
coupled to tandem mass spectrometry has facilitated the analysis of CP in short retention 
time.   
Fifteen urine samples were collected from medical personnel of Medical University 
of Gdansk, who were exposed with CP during their work in pharmacy. SPE-HPLC-MS/MS 
method was applied for the analysis of health workers and all urine samples from university 
workers has CP below analytical limit of detection.   
39  
9. REFERENCES 
1. IARC. Monographs on the evaluation of the carcinogen risk of chemicals to 
humans. No. 4, IARC. Lyon, France, 1982. 
2. K.T. Kiffmeyer, C. Kube, S. Opiolka, G.K. Schmidt, G. Schoppe, J.M.P. Sessink, 
Vapour pressures, evaporation behavior and airborne concentrations of hazards 
drugs: implications for occupational safety, Pharmeaceut J, 268(2002)331-337. 
3. T. H. Connor, M. Shults, M.P. Fraser, Determination of the vaporization of 
solutions of mutagenic antineoplastic agents at 23 and 37 C using a desiccators 
technique, Mutat Res.,470(2000)85-92. 
4. B.G. Valanis, W.M. Vollmer, K.T. Labuhn, A.G. Glass, Association of 
antineoplastic drug handling with acute adverse effects in pharmacy personnel, Am. 
J. Hosp. Pharm., 50 (1993)455-462. 
5. B. Valanis, W.M. Voller, P. Steele, Occupational exposure to antineoplastic agents: 
Self reported miscarriages and stillbirths among nurses and pharmacists, J. Occup. 
Environ. Med., 41(1999)632-638. 
6. T.T. Kensler, R. J. Behme, D. Brooke, High performance liquid chromatographic 
analysis of cyclophosphamide, J. Pharm. Sci., 68(1979)172. 
7. L.C. Burton, C.A. James, Rapid method for the determination of ifosfamide and 
cyclophosphamide in plasma by high performance liquid chromatography with solid 
phase extraction, J. Chromatogr., 431(1988)450-454. 
8. A.M. Rustum, N.E. Hoffman, Determination of cyclophosphamide in whole blood 
and plasma by reversed phase high performance liquid chromatography, J. 
Chromatogr., 422(1987)125-134 
9. M.M. Ellaithy, M. F. El-Tarras, N.B. Tadros, M. M. Amer, J. Assoc. Anal. Chem. 
67(1984)679. 
10. M.E. De Jounge, A.D.R. Huitemia, S. Rodenhuis, J. H. Beijnen, Clinical 
pharmacokinetics of cyclophosphamide, clin. Pharmacokinet. 44(2005)1135   
11. IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to man. 
Geneva: World health organization, IARC, 1972-present (Multivolume work), 
26(1981)166.  
12. C.Sottani, P. Rinaldi, E. Leoni, G. Poggi, C. Teragni, A. Delmonte, C. Minoia, 
Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, 
40  
epirubicin and daunorubicin in human urine using high performance liquid 
chromatography/ electrospray ionization tandem mass spectrometry: bioanalytical 
method validation, Rapid Commun. Mass Spectrom., 22(2008)2645-2659. 
13. M. Hirst, D.G. Millis, Tse S. Levin and D. F. White, Occupational exposure to 
cyclophosphamide, Lancet, 1(1984)186.  
14. L. Wang, C. Albansi, V. Faucet- Marquis, A. Pfohl-Leszkowicz, C. Dorandeu, B. 
Marion, C. Causserand, Cyclophosphamide removal from water by nanaofiltration 
and reverse osmosis membrane, Water Res, 43(2009)4115-4122.  
15. J. E. F. Reynolds, A. B. Prasad. (eds.) Matrindale- The extra pharmacopoeia. 28th 
ed. London: The Pharmaceutical Press, 1982, p. 199.  
16. R. J. Lewis, Sr (Ed.). Hawley’s Condensed Chemical Dictionary. 12th ed. New 
York, NY: Van Norstrand Rheinhold Co., 1993p. 341.  
17. IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to man. 
Geneva: World health organization, IARC, 1972-present (Multivolume work), 
9(1975) 136.  
18.  T. K. H. Chang, G. F. Weber, C.  L. Crespi, D. J. Waxman, Differential activation 
of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3 A in human 
liver microsomes, Cancer Res., 53(1993)5629-5637.  
19. R. F. Struck, M. C. Kirk, M. H. Witt, W. L. Russell, Isolation and mass spectral 
identification of blood metabolites of cyclophosphamide: Evidence for 
phosphoramide mustard as the biologically active metabolites, Biomed. Mass 
Spectrom., 2(1975)46-52. 
20. H. Blomgren, M. Hallstrom, Possible role of acrelein in 4-
hydroperoxycyclophosphamide induced cell damage in vitro, Methods Find Exp 
Clin Pharmacol, 13(1991)11-4   
21. D. L. Hill, W. R. Laster, R. F. Struck, Enzymatic metabolism of cyclophosphamide 
and nicotine and production of toxic cyclophosphamide metabolite, Cancer Res., 
32(1972)658-665. 
22. N. E. Sladek, Metabolism of oxazaphosphorines, Pharmacol. Ther., 37(1988)301-
355  
23. C. M. Bagley, F. W. Bostick, V. T. Devita, Clinical pharmacology of 
cyclophosphamide, Cancer Res., 33(1973)226-233. 
 
41   
24. J. Z. Fuks, M.J. Egorin, J. Aisner, S. S. Ostrow, M. E. Klein, N. R. Bachur, M. 
Colvin, P. H. Wiernik, Cyclophosphamide and dimethysulfoxide in the treatment of 
squamous carcinoma of the drug, Cancer Chemother and Pharmacol, 6(1981) 117-
120 
25. I. Jardine, C. Fenselau, M. Appler, M-N. Kan, R. B. Brundrett, M. Colvin, 
Quantitation by gas chromatography- chemical ionization mass spectrometry of 
cyclophosphamide, phosphoramide mustard and nornitrogen mustard in the plasma 
and urine of patients receiving cyclophosphamide therapy, Cancer Res., 
38(1978)408-415. 
26. M. J. Tasso, A. V. Boddy, L. Price, R. A. Wyllie, A. D.J. Pearson, J. R. Idle, 
Pharmacokinetics and metabolism of cyclophosphamide in pediatric patients, 
Cancer Chemother and Pharmacol, 30(1992)207-211.    
27. S. M. Yule, A. V. Boddy, M. Cole, L. Price, R. Wyllie, M. J. Tasso, A. D. J. 
Pearson, J. R. Idle, Cyclophosphamide metabolism in children, Cancer Res., 
55(1995)803-809.  
28. S. M. Yule, L. Price, A. D. J. Pearson, A. V. Boddy, Cyclophosphamide and 
ifosfamide metabolites in the cerebrospinal fluid of children, Clin. Cancer Res., 
3(1997)1985-1992. 
29. D. Busse, F. W. Busch, F. Bohnenstengel,M. Eichelbaum, P. Fischer, J. Opalinska, 
K. Schweizer, H. K. Kromer, Dose escalation of cyclophosphamide in patients with 
breast cancer: consequences for pharmacokinetics and metabolism, J. Clin. Oncol., 
15(1997)1885-1896. 
30. http://www.medicinenet.com/cyclophosphamide/article.htm
  
Accessed date: 10 january 2010. 
31. M. Kimura, T. Tominaga, Y. Takatsuka, M. Toi, R. Abe, H. Koyama, S. 
Takashima, Y. Nomura, S. Miura, I. Kimijima, H. Tashiro, Y. Ohashi, Randomized 
trial of cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with 
cyclophosphamide, methotrexate and fluorouracil with node positive breast cancer 
in Japan, Breast Cancer, online published 3 July 2009. 
32. M. Colleoni, A. Rocca, M. T. Sandri, L. Zorzino, G. Masci, F. Nole, G. Peruzzotti, 
C. Robertson, L. Orlando, S. Cinieri, F de Braud, G. Viale, A. Goldhirch, Low dose 
42  
oral methotrexate and cyclophosphamide in metastic breast cancer: antitumor 
activity and correlation with vascular endothelial growth factor levels, Annals of 
Onco., 13(2002)73-80 
33. S.E. Jones, B.G.M. Durie, E. Salmon, Combination chemotherapy with adriamycin 
and cyclophosphamide for advanced breast cancer, CA Cancer J  Clin,36(1975)90-
97. 
34. J.M. J. Garcia, A. Sanchez, B. Pajares, E. Perez, L. Alonso, E. Alba, Combined oral 
cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer, Clin 
Transl Oncol,10(2008)583-586. 
35. D. Raghavan, K. Cox, B.S. Pearson, G. J. Coorey, J. Rogers, W. H. Watt, A.s. 
Coates, E. McNeil, J.J. Grygiel, oral cyclophosphamide for the management of 
hormone refractory prostate cancer, British J. Urology, 72(2008)625-628. 
36. L. Brandes, S. Bracken, E. Ramsey, N,-diethy-2-[4-(phenylmethyl) phenoxy 
ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen 
for metastatic hormonally unresponsive prostate cancer, J. Clin Oncol, 13(1995) 
1398-1403. 
37. A. Nicolini, P. Mancini, P. Ferrari, L. Anselmi, G. Tartarelli, V. Bonazzi, A. Carpi, 
R. Giardino, Oral low dose cyclophosphamide in metastatic hormone refractory 
prostate cancer,  Biomed and Pharmacother, 58 (2004) 447-450.  
38. S. Bracarda, M. Tonato, P. Rosi, V. De Angelis, E. Mearini, S. Cesaroni, P. 
Fornetti, M. Porena, Oral estramustine and cyclophosphamide in patients with 
metastatic hormone refractory carcinoma , CA Cancer J  Clin, 88(2000) 1438-1444. 
39. Jr. PA. Bunn, FA. Greco, L. Einhorn, Cyclophosphamide, doxorubicin and 
etoposide as first line therapy in the treatment of small cell lung cancer, Semin 
Oncol, 3(1986)45-53. 
40. R. Arriagada, T.L. Chevalier, J.P. Pignon, A. Riviere, I. Monnet, P. Chomy, C. 
Tuchais, M. Tarayre, P. Ruffie, Initial chemotherapeutic doses and survival in 
patients with limited small cell lung cancer,  N Engl J  Med, 329(1993)1848-1852. 
41. D.T. Boumpas, H.A. Austin, J.E. Balow, E. M. Vaughan, C. H. Yarboro, J.H. 
Klippel, A. D. Steinberg, Controlled trial of pulse methylprednisone versus two 
regimens of pulse cyclophosphamide in severve lupus nephritis, The Lancet, 
340(1992) 741-745. 
43  
42. M. F. Gourley, H. A. Austin, D. Scott, C. H. Yarboro, E. M. Vaughan, J. Muir, D. 
T. Boumpas, J. H. Klippel, J. E. Balow, A. D. Steinberg, Methylprednisolone and 
cyclophosphamide alone or in combination, in patients with lupus nephritis: A 
randomized, control trial, Ann of Intern med, 125(1996) 549-557. 
43. C.A. Wallace, D.D Sherry, Trial of intravenous pulse cyclophosphamide and 
methyprednisolone in the treatment of  severe systemic-onset juvenile rheumatoid 
arthritis, Arthritis care and research, 40(2005)40. 
44. H. J. Williams, J. C. Reading, J. R. Ward, W.M. O’Brien, Comparison of high low 
dose cyclophosphamide therapy in rheumatoid arthritis, Arthritis care and research, 
23(2005) 521-527. 
45. D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. 
Christodoulou, E. locher, P. K. Coyle, High dose cyclophosphamide for moderate to 
severe refractory multiple sclerosis, Arch Neurol., 63(2006)1388-1393. 
46. B. W. Guttman, R. P. Kinkel, J. A. Cohen, R. M. Ransohoff, K. Schwetz, D. Gogol, 
M. Namey, R. A. Rudick, Treatment of fulminant multiple sclerosis with 
intravenous cyclophosphamide, The Neurologist, 3(1997) 186. 
47. R.P. Baughman, E. E. Lower, Use of intermittent, intravenous cyclophosphamide 
for idiopathic pulmonary fibrosis, Chest, 102(1992) 1090-1094. 
48. D. A. Zisman, J. P. Lynch III, G. B. Toews, E. A. Kazerooni, A. Flint, F. J. 
Martinez, Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: A 
prospective study in patients who failed to respond to corticosteroids, Chest, 
117(2000)1619-1626. 
49. L. Guillevin, J. F. Cordier, F. Lhote, P. Cohen, B. Jarrouse, I. Royer, P. Lesavre, C. 
Jacquot, P. Bindi, P. Bielefeld, J. F. Desso, F. Detree, A. Dubois, E. Hachulia, B. 
Hoen, D. Jacomy, C. Seigneuric, D. Lauqque, M. Stern, M. L. Boursier, Arthritis 
and rheumatism, 40(1997)2187-2198. 
50. M. Haubitz, U. Frei, U. Rother, R. Brunkhorst, K. M. Koch, Cyclophosphamide 
pulse therapy in Wegener granu;omatosis, Neprol Dial Transplant 6(1991)531-535. 
51.  M. J. Reza, L. Dornfeld, L. S. Goldberg, R. Bluestone, C. M. Pearson, Wegener 
granulomatosis, Arthritis care and research, 18(2005)501-506. 
52. A. Fabbri, M. Lenoci, A. Gozzetti, I. Chitarrelli, F. Olcese, D. Raspadori, M. Gobbi, 
F. Lauria, Low dose oral fludarabine plus cyclophosphamide as first line treatment 
44  
in elderly patients with indolent non- Hodgkin lymphomas, Brit J Haematol, 
139(2007)90-93. 
53. R. I. Fisher, E. R. Gaynor, S. Dahlberg, M. M. Oken, T. M. Grogan, E. M. Mize, J. 
H. Glick, C. A. Coltman, T. P. Miller, Comparison of a standard regimen with three 
intensive chemotherapy regimens for advanced non- hodgkin’s lymphoma, Annals 
of Internal medicine, 328 (1993)1002- 1006. 
54. P. Sonneveld, M. de Ridder, H. van der Lelie, K. Nieuwenhius, H. Schouten, A. 
Mulder, I van Reijswould, W. Hop, B. Lowenberg, Comparison of doxorubicin and 
mitoxantrone in the treatment of elderly patients with  advance diffuse non – 
hodgkin’s lymphoma using CHOP versus CNOP chemotherapy, J. Clinic. Oncol., 
13() 2530-2539 
55. A. Reiner, T. Gernsheimer, S. Slichter, Pulse cyclophosphamide therapy for 
refractory autoimmune thrombocytopenic purpura, 85(1995) 351- 358. 
56. M. Verlin, R. K. Laros, J. A. Penner, Treatment of refractory thrombocytopenic 
purpura with cyclophosphamide, American Journal of Hematology 1(2006)97-104. 
57. R.K. Laros, J. A. Penner, Refractory thrombocytopenic purpura treated successfully 
with cyclophosphamide, JAMA, 215(1971)445-449. 
58. P. Sanchez, J. Anguita, T. Pintado, Use of cyclophosphamide in the treatment of 
thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus: 
report of two cases, Annals of Hematology, 78( 1999)285-287. 
59. A. Fauci, J. Doppman, S. Wolff, Cyclophosphamide induced remissions in 
advanced polyarteritis nodosa, Am J Med., 64(1978) 890-894. 
60. V. M. Moyo, D. Smith, I. Brodsky, P. Crilley, R. J. Jones, R. A. Brodsky, High dose 
cyclophosphamide for refractory autoimmune hemolytic anemia, Blood, 100(2002) 
704-706. 
61. R. A. Brodsky, A. R. Chen, I. Brodsky, R. J. Jones, High dose cyclophosphamide as 
salvage therapy for severe aplastic anemia, Experimental Hematology, 32( 2004) 
435-440. 
62. D. Barcelo, M.-C. Hennion, in: Determination of Pesticides and Their Degradation 
Products in Water, Elsevier, Amsterdam, 1997, pp. 249–356. 
63. E.M. Thurman, M.S. Mills, Solid-Phase Extraction Principles and Practice, Wiley, 
New York, 1998 
45  
64. N.J.K. Simpson, Solid Phase Extraction – Principles Strategies and Applications, 
Marcel Dekker, New York 1998. 
65. R.E. Majors, New designs and formats in solid phase extraction sample preparation, 
LC/GC Int. September (1998) 8–16. 
66. C.F. Poole, New trends in solid phase extraction, Tr in Anal.  Chem., 6(2003)362-
373. 
67. M.C. Hennion, C. Cau-Dit-Coumes, V. Pichon, Trace analysis of polar organic 
pollutants in aqueous samples: tools for the rapid prediction and optimization of the 
solid phase extraction parameters, J. Chromatogr. A, 823 (1998) 147. 
68.  M.C. Hennion, Solid phase extraction: method development, sorbents and coupling 
with liquid chromatography, J. Chromatogr. A, 856(1999)3-54. 
69. C. Sottani, R. Turci, L. Perbellini, C. Minoia, Liquid- Liquid extraction procedure 
for trace determination of cyclophosphamide in human urine by high performance 
liquid chromatography tandem mass spectrometry, Rapid Commun. Mass 
Spectrom., 12(1998)1063-1068. 
70. D. Kasel, A.  Jetter, S. Harlfinger, W. Gebhardt, U. Fuhr, Quantification of 
cyclophosphamide and its metabolites  in urine using liquid chromatography/ 
tandem mass spectrometry, Rapid Commun. Mass Spectrom., 18(2004) 1472-1478. 
71. A. Barbieri, L. Sabatini, P. Indiveri, R. Bonfiglioli, V. Lodi, F. s. Violante, 
Simultaneous determination of low levels of methotraxate and cyclophosphamide in 
human urine by micro liquid chromatography/ electrospray ionization tandem mass 
spectrometry, Rapid Commun. Mass Spectrom., 20(2006)1889-1893. 
72. B. Karahalil, K.I. Akkoyunlu, Determination of urinary cyclophosphamide in 
oncology nurses handling antineoplastic drugs by gas chromatography-mass 
spectrometry, J. Pharm. Sci., 28 (2003)125-130 
73. M. Hedmer, P. Hoglund, E.Cavallin- Stahl, M. Ablin, A. G. Jonsson; Validation of 
urinary excretion of cyclophosphamide as biomarker of exposure by studying its 
renal clearance at high and low plasma concentrations in cancer patients; Int. Arch. 
Occup. Environ. Health; 81 (2008)285-293. 
74. R. Difrancesco, J.J. Griggs, J. Donnelly, R. Dicenzo, Simultaneous analysis of 
cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography 
coupled to tandem mass spectrometry, J. Chromatogr. B, 852(2007)545-553. 
46   
75. C. Ekhart, A. Gebretensae, H. Rosing, S. Rodenhuis, Jos H. Beijnen, A.D.R. 
Huitema, Simultaneous quantification of cyclophosphamide and its active 
metabolite 4- hydroxycyclophosphamide in human plasma by high performance 
liquid chromatography coupled with electrospray ionization tandem mass 
spectrometry, J. Chromatogr. B, 854(2007)345-349. 
76. L. Sabatani, A. Barbieri, M. Tosi, F.S. Violante, A new high performance liquid 
chromatographic/ electrospray ionization tandem mass spectrometric method for the 
simultaneous determination of cyclophosphamide, methotrexate and 5- fluorouracil 
as markers of surface contamination for occupational exposure monitoring, J. Mass 
spectrum., 40(2005)669-674. 
77. F. Baumann, C. Lorenz, U. Jaehde, R. Preiss, Determination of cyclophosphamide 
and its metabolites in human plasma by high performance liquid chromatography- 
mass spectrometry, J. Chromatogr. B, 729(1999)297-305. 
78. T.F.Kalhorn, S. Ren, W.N. Howald, R.F. Lawrence,J. T. Slattery, Analysis of 
cyclophosphamide and five metabolites from human plasma using liquid  
chromatography- mass spectrometry and gas chromatography nitrogen phosphorous 
detection, J. Chromatogr. B, 732(1999)287-298. 
79. I. Martins, J. O. Souza, A. L. Sanson, E. P. Vieira, A. G. Paiva, Simultaneous 
determination of cyclophosphamide and ifosfamide in plasma using SPE-
HPLC_UV methods,  Lat. Am. J. Pharm, 28(2009)41-6 
80. C. Sottani, R. Turci, R. Schierl, R. Gaggeri, A. Barbieri, F. S. Violante, C. Mionia, 
Simultaneous determination of gemcitabine, taxol, cyclophosphamide and 
ifosfamide in wipe samples by high performance liquid chromatography/ tandem 
mass spectrometry: protocol of validation and uncertainty of measurement, Rapid 
Commun. Mass Spectrom., 21(2007)1289-1296. 
81. M. Tanimura, K. Yamada, S. Sugiura, K. Mori, H. Nagata, K. Tadokora, T. Miyake, 
Y. Hamaguchi, P. Sessink, T. Nabeshima,  An environmental and biological study 
of occupational exposure to cyclophosphamide in the pharmacy of a Japanese 
community hospital designated for the treatment of cancer, J. health science, 
55(2009)750-756.  
47  
82. W. Fransma, S. Peelen, S. Hilhorst, N. Roeleveld, D. Heederik, H. Kromhout, A 
polled analysis to study trends in exposure to antineoplastic drugs among nurses, 
Ann. Occup. Hyg., 51(2007)231-239.  
83. C. Minoia, R. Turci, C. Sottani, A. Sehiavi, L. Perbellini, S. Angeleri, F. Draicchio, 
P. Apostoli, Application of high performance liquid chromatography/ tandem mass 
spectrometry in the environmental and biological monitoring of health care 
personnel occupationally exposed to cyclophosphamide and ifosfamide, Rapid 
Commun. Mass Spectrom., 12(1998)1485-1493. 
84. C. Sottani, R. Turci, R. Schierl, R. Gaggeri, A. Barbieri, F. S. Violante, C. Mionia, 
Simultaneous determination of gemcitabine, taxol, cyclophosphamide and 
ifosfamide in wipe samples by high –performance liquid chromatography/ tandem 
mass spectrometry: protocol of validation and uncertainty of measurement, Rapid 
Commun. Mass Spectrom., 21(2007)1289-1296. 
85. N. Sadagopan, L. Cohen, B. Roberts, W. Collard, C. Omer, Liquid chromatography-
tandem mass spectrometric quantitation of cyclophosphamide and its hydroxyl 
metabolite in plasma and tissue for determination of tissue distribution, J. 
Chromatogr. B, 759(2001)277-284. 
86. T.F. Kalhorn, W.N. Howald, S. Cole, B. Phillips, J. Wang, J. T. Slattery, J.S. 
McCune, Rapid quantitation of cyclophosphamide metabolites in plasma by liquid 
chromatography-mass spectrometry, J. Chromatogr.,835(2006)105-113.     
This document was created with Win2PDF available at http://www.win2pdf.com.
The unregistered version of Win2PDF is for evaluation or non-commercial use only.
This page will not be added after purchasing Win2PDF.
